IVIEW announces successful completion of in-vitro virucidal study of IVIEW-1503, a safe, non-toxic and long-lasting Povidone Iodine nasal spray for the prevention and treatment of COVID-19

[May 20, 2020] Doylestown, Pennsylvania–IVIEW Therapeutics Inc., an innovative clinical stage specialty pharmaceutical company is proud to announce the successful completion of in-vitro virucidal study of IVIEW-1503, a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19. The result was published on bioRxiv preprint doi: https://doi.org/10.1101/2020.05.18.103184 titled[…]

IVIEW completed pre-IND meeting with FDA for the development of IVIEW-1501/1502 for the treatment of Chronic Rhinosinusitis (CRS)

[April 14, 2020] Doylestown, Pennsylvania –IVIEW Therapeutics Inc., an innovative, clinical-stage biopharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, and otolaryngology, completed a successful pre-IND meeting with FDA to develop IVIEW-1501/1502 (Povidone Iodine in combination of Budesonide Nasal Irrigation and Nasal Spray Compositions) for the[…]

iVIEW is developing a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 infection to curb the COVID-19 spread

[April 5, 2020] Doylestown, Pennsylvania – IVIEW Therapeutics Inc., an innovative clinical stage specialty pharmaceutical company that is committed to becoming a leader in topical drug development with specialization in ophthalmology is currently developing treatment and prevention strategies against the novel SARS-CoV-2, also known as, COVID-19.[…]

iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis

[December 19, 2019] Doylestown, Pennsylvania — iView Therapeutics Inc. today announced that the first patient has been treated in the Phase 2 IVIEW-1201-01-AIC clinical trial program accessing the efficacy of IVIEW-1201 for adolescent and adult patients (age ≥15 years) with Acute Adenoviral Conjunctivitis. First subject was dosed on 19 Dec in India at Disha Eye Hospital Pvt. Ltd. Kolkata under this Phase II Clinical trial program. This study is planned in US, India and China simultaneously.[…]

iVIEW-1201 Phase II IND clinical trial application for the Treatment of Adenoviral Conjunctivitis approved by Indian Regulatory Authority (CDSCO)

[June 6, 2019] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., an innovative specialty pharmaceutical company committed to becoming a leader in topical drug development with specialization focus on ophthalmology, today announced that its Phase II clinical trial IND application of iVIEW-1201 for the Treatment of Adenoviral Conjunctivitis has been approved by Indian Regulatory Authority, CDSCO.[…]

iVIEW Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

[April 11, 2019] Doylestown, Pennsylvania–iVIEW Therapeutics Inc., a clinical-stage biotechnology company focusing on topical drug development on the areas of ophthalmology, otolaryngology, and dermatology, today announced that it has been awarded a Small Business Innovation Research (SBIR) Year 2 Award of $300,000 from National Institute of Allergy and Infectious Diseases (NIAID) at National[…]